• Recombinant Mouse SHH: Strategic Advances in Developmental B

  2026-05-08

  Explore the mechanistic and translational power of Recombinant Mouse Sonic Hedgehog (SHH) protein, with actionable guidance for leveraging this morphogen in limb and brain patterning, congenital malformation studies, and alkaline phosphatase induction assays. This article interprets recent comparative developmental findings, details protocol parameters, and positions APExBIO’s SHH as a linchpin for reproducibility and innovation in hedgehog signaling research.

• BIBR 1532: Telomerase Inhibitor Workflows & Assay Optimizati

  2026-05-07

  Harnessing BIBR 1532 in telomerase activity assays enables precise inhibition of telomerase, robust apoptosis induction, and reproducible cancer cell proliferation studies. This guide translates reference-backed mechanisms and troubleshooting strategies into actionable workflows for translational oncology labs.

• Meta-Analysis Validates Tamsulosin for Ureteral Stone Expuls

  2026-05-07

  A recent systematic review and meta-analysis rigorously evaluated the efficacy of Tamsulosin for symptomatic ureteral stone expulsion, synthesizing data from 49 studies involving over 6,400 patients. The findings confirm that Tamsulosin significantly increases stone clearance rates and reduces expulsion time without a notable rise in adverse effects, providing robust guidance for translational urological research.

• CDC20 Inhibition Triggers Pyroptosis and Boosts Immunity in

  2026-05-06

  Wu et al. (2023) reveal that CDC20 suppresses immunogenic cell death by targeting GSDME for proteasomal degradation in prostate cancer. Their findings show that CDC20 inhibition shifts cell fate from apoptosis to pyroptosis, enhancing anti-tumor immune responses and sensitizing tumors to immunotherapy.

• EZ Cap™ mCherry mRNA: Precision Redox Biosensing & Expressio

  2026-05-06

  Discover how mCherry mRNA enables advanced redox biosensor assays and robust fluorescent protein expression with low immunogenicity. Explore its unique role in metabolic monitoring beyond conventional reporter gene mRNA applications.

• Rucaparib (AG-014699): Optimizing DNA Damage Response Resear

  2026-05-05

  Rucaparib (AG-014699) is a benchmark PARP1 inhibitor enabling precise DNA damage response research, with exceptional radiosensitizing effects in PTEN-deficient and ETS gene fusion-expressing cancer models. This article delivers hands-on workflow enhancements, troubleshooting strategies, and actionable insights for maximizing reproducibility and sensitivity in advanced cancer biology applications.

• CFDA SE Cell Tracer Kit: Technical Guidance for Cell Trackin

  2026-05-05

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit enables reproducible, long-term cell labeling for cell proliferation studies and cell lineage tracing. It is most suitable for workflows that require stable, covalent, and minimally cytotoxic fluorescent cell tracking, but should not be used where reversible or short-term labeling is necessary.

• CPI-613: Redefining Tumor Metabolism Assays via Mitochondria

  2026-05-04

  Explore how CPI-613, a pyruvate dehydrogenase complex inhibitor, revolutionizes tumor cell metabolism studies and apoptosis assays. This article reveals unique mitochondrial control points and new experimental frameworks, informed by cutting-edge research.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-04

  Schwartz's dissertation establishes a nuanced framework for in vitro assessment of anti-cancer drugs, distinguishing growth inhibition from cell death to improve interpretation of therapeutic efficacy. Her findings have immediate implications for designing more precise drug screening workflows, particularly for multi-target agents like Pazopanib Hydrochloride.

• Neuromedin S (rat): Technical Guidance for GPCR Assays

  2026-05-03

  Neuromedin S (rat) serves as a chemically defined endogenous agonist for neuromedin U receptor signaling, supporting reproducibility in GPCR/G protein pathway research. It is intended exclusively for controlled laboratory workflows, with strict handling and storage requirements. This product is not to be used for diagnostic or therapeutic purposes.

• Rosiglitazone (Brl-49653): Reframing Metabolic Therapeutics

  2026-05-02

  This thought-leadership article examines how Rosiglitazone (Brl-49653), a synthetic thiazolidinedione and PPARγ agonist, elevates translational metabolic research by bridging mechanistic insights in adipogenesis, insulin sensitivity, and mitochondrial function with strategic workflow guidance. Drawing on new findings in beige adipocyte differentiation and thermogenesis (SEMA3E/β-catenin axis), the article offers actionable protocol parameters, competitive analysis, and future-facing perspectives for researchers aiming to model and modulate metabolic disease.

• BCA Protein Assay Kit: Precision Quantification for BBB Pyro

  2026-05-02

  Uncover how the BCA Protein Assay Kit enables high-precision bicinchoninic acid protein quantification in blood–brain barrier (BBB) pyroptosis studies. This in-depth article goes beyond standard guides to examine assay selection, experimental nuances, and translational impact in neuroinflammatory research.

• Dacarbazine in Precision Oncology: Quantifying Cytotoxicity

  2026-05-01

  Discover how Dacarbazine, a leading antineoplastic chemotherapy drug, enables advanced cytotoxicity quantification in cancer research. This article uniquely explores in vitro drug response metrics and practical protocol parameters for translational oncology.

• EdU Imaging Kits (488): Precision S-Phase Detection via Clic

  2026-04-30

  EdU Imaging Kits (488) enable rapid, high-sensitivity cell proliferation analysis by leveraging 5-ethynyl-2'-deoxyuridine and click chemistry. This workflow-friendly solution preserves cell integrity and outperforms BrdU methods, supporting advanced cancer and cell cycle research.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel

  2026-04-30

  This study uncovers a synergistic effect between ATM kinase inhibition and the metabolic modulator fenofibrate in high grade serous ovarian cancer (HGSOC) cells. The findings highlight metabolic vulnerabilities in HR-proficient tumors, suggesting new avenues for combination therapies beyond DNA repair targeting.

453 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page